Skip survey header

Clinical and Hearing Management of Infants Identified on Cytomegalovirus (CMV) Screening with Congenital CMV Infection – What to do With all the Babies?

National Center for Hearing Assessment and Management

Clinical and Hearing Management of Infants Identified on Cytomegalovirus (CMV) Screening with Congenital CMV Infection – What to do With all the Babies?

Presented by: Karen Fowler  |  July 19th, 2018 

Webinar start times (by time zone)

  • 12:00 pm - 1:00 pm PT
  • 1:00 pm - 2:00 pm MT
  • 2:00 pm - 3:00 pm CT
  • 3:00 pm - 4:00 pm ET

With increasing interest in screening for congenital CMV infection (cCMV), many more children with cCMV are being identified. Implementation of targeted CMV screening, within newborn hearing screening, in multiple states along with individual hospitals elsewhere is leading to identification of infants with cCMV that would have previously gone undetected. Approximately 15% of clinically inapparent (asymptomatic) cCMV infants will have hearing loss during early childhood years but less is known about developmental disabilities in the asymptomatic cCMV infant. Current clinical and antiviral treatment recommendations apply to infants with symptomatic cCMV. However, it is unclear what the appropriate clinical evaluation and management is for the asymptomatic cCMV infant who is at risk for CMV sequelae, although to a lesser degree than the infants with symptomatic disease. How should the asymptomatic infant with isolated hearing loss at birth or an infant with asymptomatic infection with no hearing loss at birth be clinically managed? Should all asymptomatic infants undergo full laboratory and neuroimaging evaluations? Is there evidence for treatment of infants with asymptomatic cCMV with antivirals? How often should cCMV infants or children have audiological assessments and until what age? This session will summarize the current literature, data from UAB's earlier cohort and the CHIMES study to develop a proposed clinical management and hearing algorithm for the asymptomatic cCMV infant. In addition, we will address the gaps in our knowledge where more data are needed for the clinical management of infants with asymptomatic cCMV.

  • Review definitions of symptomatic and asymptomatic congenital CMV infection
  • Discuss data on congenital CMV infection used to develop a clinical management and hearing algorithm
  • Discuss current gaps in our knowledge about asymptomatic congenital CMV infection

Karen Fowler, University of Alabama at Birmingham (UAB) 

Karen B. Fowler, DrPH, is a professor in the Department of Pediatrics at the UAB School of Medicine. Her research focuses on the epidemiology, natural history, and pathogenesis of maternal and congenital cytomegalovirus infections and CMV-related hearing loss in children.

Once you have submitted the registration information, a confirmation email will be sent to your email address with additional webinar participation/ login information. Please contact Mandy McClellan if you have not received a confirmation email two days prior to the webinar.